Cargando…
Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094406/ https://www.ncbi.nlm.nih.gov/pubmed/35574017 http://dx.doi.org/10.3389/fendo.2022.899616 |
| _version_ | 1784705528889344000 |
|---|---|
| author | Pivonello, Rosario Bancos, Irina Feelders, Richard A. Kargi, Atil Y. Kerr, Janice M. Gordon, Murray B. Mariash, Cary N. Terzolo, Massimo Ellison, Noel Moraitis, Andreas G. |
| author_facet | Pivonello, Rosario Bancos, Irina Feelders, Richard A. Kargi, Atil Y. Kerr, Janice M. Gordon, Murray B. Mariash, Cary N. Terzolo, Massimo Ellison, Noel Moraitis, Andreas G. |
| author_sort | Pivonello, Rosario |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9094406 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90944062022-05-12 Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study Pivonello, Rosario Bancos, Irina Feelders, Richard A. Kargi, Atil Y. Kerr, Janice M. Gordon, Murray B. Mariash, Cary N. Terzolo, Massimo Ellison, Noel Moraitis, Andreas G. Front Endocrinol (Lausanne) Endocrinology Frontiers Media S.A. 2022-04-27 /pmc/articles/PMC9094406/ /pubmed/35574017 http://dx.doi.org/10.3389/fendo.2022.899616 Text en Copyright © 2022 Pivonello, Bancos, Feelders, Kargi, Kerr, Gordon, Mariash, Terzolo, Ellison and Moraitis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Endocrinology Pivonello, Rosario Bancos, Irina Feelders, Richard A. Kargi, Atil Y. Kerr, Janice M. Gordon, Murray B. Mariash, Cary N. Terzolo, Massimo Ellison, Noel Moraitis, Andreas G. Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study |
| title | Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study |
| title_full | Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study |
| title_fullStr | Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study |
| title_full_unstemmed | Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study |
| title_short | Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study |
| title_sort | corrigendum: relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with cushing syndrome: results from a prospective, open-label phase 2 study |
| topic | Endocrinology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094406/ https://www.ncbi.nlm.nih.gov/pubmed/35574017 http://dx.doi.org/10.3389/fendo.2022.899616 |
| work_keys_str_mv | AT pivonellorosario corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT bancosirina corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT feeldersricharda corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT kargiatily corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT kerrjanicem corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT gordonmurrayb corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT mariashcaryn corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT terzolomassimo corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT ellisonnoel corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study AT moraitisandreasg corrigendumrelacorilantaselectiveglucocorticoidreceptormodulatorinducesclinicalimprovementsinpatientswithcushingsyndromeresultsfromaprospectiveopenlabelphase2study |